Tell us what you think about the new Article Page. Send us feedback
Reportlinker Adds Evolving Trends in Biopharmaceutical Licensing: Deal Assessments, Drivers and Resistors Report
NEW YORK--(BUSINESS WIRE)--Reportlinker.com announces that a new market research report is available in its catalogue.
Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors
Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors
Large Pharma companies have become heavily dependant upon alliances and in-licensing to gain access to technologies/new molecular entities from Biopharma. This reliance has strengthened Biopharma’s bargaining position, and is reflected in negotiation tactics which aim to expand their role beyond product discovery and development towards an active participation in the the future of their products. This is emphasized by the growing complexity of licensing deals, as Biopharma attempts to secure marketing and commercialization rights within partnership deals.
Furthermore, recent increases in internal Biopharma consolidation are an indicator of the ability of well-established Biopharma companies to effectively compete against traditional big Pharma.
‘Evolving Trends in Biopharmaceutical Licensing’ is a report published by Business Insights that provides a detailed analysis of licensing strategies in the biopharmaceutical industry over the 2001-08 period. This report examines the growth of the biopharmaceutical industry, deal-making trend data, drivers and challenges facing biopharmaceutical licensing, and profiles of biopharmaceutical licensing among leading companies. The future prospects of the industry are assessed and the potential impact of political/regulatory factors upon licensing and alliances is identified. This report also investigates the influence of the recent upsurge in M&A activity and provides recommendations on the strategies that can sustain future growth.
Key Findings
-Several top-ranked Biopharma companies have matched the consistent sales growth of major traditional pharma companies. A key component of this success has been the increasing reliance of big Pharma to improve R&D productivity and rejuvenate sales of marketed portfolios through licensing and partnership deals.
-Big Pharma has been acquiring Biopharma companies at an increasing rate, resulting in this becoming the fastest-growing M&A sector in 2008 with deal values up 87%. Intense competition and financial uncertainty has also prompted a surge in biopharma consolidation, with 52 biopharma/biopharma deals in 2007.
-Considerable potential for Biopharma licensing deals still exists, particularly within the OAD class of drugs and non-invasive insulin drug delivery technologies.
-The total deal size of early-stage alliances with biopharma has increased six-fold, with total deal values in 2007 estimated at $18bn. This has been driven by the relatively lower costs of discovery and lead development, despite the higher risk of failure.
-Co-development/co-promotion deals accounted for 30% of licensing deals over 2006-07. Licensing deals will continue to become more complex due to biopharma’s desire to remain involved in their product lifecycle beyond the stages of discovery and development
Use this report to...
• Examine the licensing landscape of the biopharma industry with this report’s analysis of Biopharma and Pharma licensing and alliance activity and an examination of specific approaches utilized by both sectors.
• Discover the drivers and challenges facing Biopharma licensing, understand how
Biopharma companies are preparing to exploit new opportunities and assess deal-making trends across clinical trials phases and key therapeutic areas.
• Evaluate the strategies of leading companies involved in biopharmaceutical licensing with this report’s analysis of deal activities amongst leading players and identify the changing dynamics of Biopharma/Pharma partnerships.
• Assess the future prospects of the Biopharma industry and how current market and political/regulatory factors will impact the dynamics of licensing and alliances, as well as potential strategies for sustaining growth.
Explore issues including...
Biopharmas reduced reliance on Pharma. Biopharma is sustaining its efforts to increase its role outside of product development/discovery to become actively engaged in the future of their products. As such, it is becoming increasingly difficult to differentiate big Pharma from major Biopharma companies.
Optimizing revenue potential. Biopharma are increasingly targeting high value therapy areas, such as oncology and inflammatory disease, bringing them into direct competition with major Pharma.
Future competitive strategies. With licensing deals increasing in value and complexity, Biopharma companies are looking to increase their involvement by forming long-term, partnership-based relationships. This active engagement in licensing deals will typically involve the negotiation of equity investment and the co-promotion and co-marketing of a drug that allows Biopharma to generate additional downstream revenues.
Drug development potential. The emergence of several new Biopharma companies with innovative technology platforms has created immense potential for intra-Biopharma licensing trends to continue developing novel drugs that can successfully differentiate themselves within the marketplace.
Discover...
• How will the increasing competition for attractive Biopharma licensing candidates affect deal terms and values?
• How can Biopharma companies improve their licensing strategies to ensure future growth?
• What have been the major trends in licensing agreements between Biopharma and Pharma over 2001-08?
• Which strategies have Biopharma used to reduce their reliance on Pharma?
• How has the value, volume and competition for Biopharma licensing deals changed over 2001-08?
• What have been the strategies of successful Biopharma and Pharma deal-makers?
• Why are Biopharma and Pharma increasingly adopting M&A strategies instead of entering into licensing agreements?
Table of Contents
Evolving Trends in Biopharmaceutical Licensing Executive Summary 10
Introduction to biopharmaceutical licensing 10
Biopharmaceutical deals and trends 11
Drivers and resistors facing biopharmaceutical licensing 12
Companies involved in biopharmaceutical licensing 13
The evolutionary pattern of biopharmaceutical licensing 14
Chapter 1 Introduction to biopharmaceuticals and licensing 16
Summary 16
Introduction 17
Overview of the biopharmaceutical industry 17
The Biopharma-Pharma relationship 18
The licensing process 21
Meeting the licensing challenge 22
Biopharma continues to shine 24
Chapter 2 Biopharmaceutical deals and trends 26
Summary 26
Introduction 27
Biopharmaceutical licensing trends 27
Number and average value of Biopharma licensing deals 28
Licensing deal partners 30
Biopharma’s standing: out-licensing versus in-licensing deals 31
Licensing deal types 32
Licensing trends in drug development 34
The rising costs of early-stage licensing 35
Mid-stage deal-making: lucrative prospects 40
Therapeutic focus in Biopharma licensing 41
Chapter 3 Drivers and resistors of biopharmaceutical licensing 44
Summary 44
Introduction 45
Overview of drivers and resistors in biopharmaceutical licensing 45
Key drivers 46
Generating cash 46
Pharma turns to Biopharma to maintain revenue growth; Biopharma gaining an upper hand 48
Risk sharing 50
Access to expertise 50
Key resistors 52
Reduced control 52
Increasing complexity of licensing deals: positive for Biopharma but with a higher risk attached 52
Stricter regulatory and political environments 53
Future strategic direction 58
Chapter 4 Leading companies involved in biopharmaceutical licensing 62
Summary 62
Introduction 63
Who is looking to Biopharma and why? 63
Two sides of the Pharma coin: GlaxoSmithKline and Roche 64
GlaxoSmithKline: a Biopharma façade? 64
Roche: building upon an established presence in Biopharma 71
The Biopharma/Pharma dynamic 76
Amgen: the leading Biopharma 76
Gilead: diversification after market domination 80
Cephalon: a Biopharma out-licensor 83
Alnylam: a developer of novel therapeutics based on RNA interference 85
Chapter 5 The evolutionary pattern of biopharmaceutical licensing 90
Summary 90
Introduction 91
The big deals of 2008: a sign of what is to come? 91
Who holds the future to ImClone? 91
The Roche and Genentech saga 92
Biopharma to Biopharma: Genzyme and Isis 93
Takeda looks to Biopharma for entry to the US market 94
Pfizer and Wyeth 95
Are M&As the new licensing? 97
Potential arrival of biosimilars: a catalyst for Biopharma M&A 98
The financial crisis and the future of Biopharma 99
The promise of emerging markets 101
Keys to future success 104
Recommendations and strategies for future Biopharma licensing deals and alliances 105
Chapter 6 Appendix 110
MedTRACK data 110
Index 111
List of Figures
Figure 1.1: Number of NMEs and BLAs approved by the US FDA 19
Figure 1.2: Strengths of Biopharma and Pharma 21
Figure 1.3: Overview of the pharmaceutical licensing process 23
Figure 1.4: Global sales* of Biopharma vs. Pharma 24
Figure 2.5: Number and average value of Biopharma licensing deals, 2001–08 28
Figure 2.6: Number of top 20 Biopharma licensing deals by partner, 2001–08 30
Figure 2.7: Number of Biopharma in- and out-licensing deals by partner, 2004–08 31
Figure 2.8: Biopharma licensing by deal type, 2001–08 32
Figure 2.9: Biopharma out-licensing distribution by clinical stage, 2001–08 34
Figure 2.10: Early-stage deal models with associated pros & cons 36
Figure 2.11: Early-stage alliances—number of deals and deal size, 2001–08 37
Figure 2.12: Trends in technology, Biopharma out-licensing, 2002–07 38
Figure 2.13: Number of Biopharma out-licensing deals ($100m+ nominal deal value) by clinical stage, 2005–08 40
Figure 2.14: Therapeutic focus in Biopharma licensing deals, 2005–08 41
Figure 3.15: Drivers and resistors facing biopharmaceutical licensing 46
Figure 3.16: Biopharma R&D spend 47
Figure 3.17: Biopharma funding 47
Figure 3.18: Progression of Biopharma’s involvement in licensing deals 49
Figure 3.19: Estimated last patent expiry dates of selected proteins 56
Figure 3.20: Future strategic directions for Biopharma in meeting current challenges 58
Figure 4.21: Biopharma’s transition via forward and downward integration 64
Figure 5.22: Announced number of Biopharma mergers & acquisitions, 2001–08 97
Figure 5.23: Drug patent expiries in the US, 2008-2012 100
Figure 5.24: Future licensing and alliance scenarios for Biopharma 104
List of Tables
Table 4.1: GSK’s licensing and alliance activity, 2008 67
Table 4.2: GSK’s licensing and alliance activity, 2007 68
Table 4.3: GSK’s licensing and alliance activity, 2006 69
Table 4.4: GSK’s licensing and alliance activity, 2005 70
Table 4.5: Roche’s licensing and alliance activity, 2008 71
Table 4.6: Roche’s licensing and alliance activity, 2007 72
Table 4.7: Roche’s licensing and alliance activity, 2006 73
Table 4.8: Roche’s licensing and alliance activity, 2005 74
Table 4.9: Amgen’s licensing and alliance activity, 2007-08 77
Table 4.10: Amgen’s licensing and alliance activity, 2005-06 78
Table 4.11: Gilead’s licensing and alliance activity, 2005–07 80
Table 4.12: Cephalon’s licensing and alliance activity, 2005–07 83
Table 4.13: Alnylam’s licensing and alliance activity, 2005–07 85
Table 5.14: Sales in 7MM and pharmerging markets ($m), 2003-07 101
To order this report:
Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors
More market research reports here!
Contact:
Reportlinker
Nicolas: nbo@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626
Top Stories
Tech Ticker Recent Posts
Add Alert Copyright © 2009 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials by posting, archiving in a public web site or database, or redistribution in a computer network is strictly forbidden.